**Financial Conflicts of Interest Checklist for Clinical Research Studies**

**Word count Text: 2649**

**Number of Figure: 1**

**Number of Tables: 3**

**Number of Appendix: 3**

**Number of Supplements: 1**

Paula A. RochonMD MPH

Women’s College Research Institute at Women's College Hospital, Toronto

John Hoey MD

Dalla Lana School of Public Health, University of Toronto, Toronto

An-Wen Chan MD DPhil

Women’s College Research Institute at Women's College Hospital, Toronto

Lorraine E. Ferris PhD LLM

Dalla Lana School of Public Health, University of Toronto, Toronto

Joel Lexchin MSc MD

School of Health Policy and Management, York University, Toronto

Emergency Department, University Health Network, Toronto

Department of Family and Community Medicine, University of Toronto, Toronto

Sunila R. Kalkar MBBS MD M Ed

Women’s College Research Institute and Women's College Hospital, Toronto

Melanie Sekeres MSc

Department of Physiology University of Toronto, Toronto

Wei Wu MSc

Women’s College Research Institute and Women's College Hospital, Toronto

Marleen Van Laethem MHSc

Toronto Rehabilitation Institute, Toronto

Joint Centre for Bioethics, University of Toronto, Toronto

Andrea Gruneir PhD

Women’s College Research Institute and Women's College Hospital, Toronto

Baycrest– Kunin Lunenfeld Applied Research Unit Toronto, Toronto

M James Maskalyk MD

Division of Emergency Medicine, University of Toronto, Toronto

David L. Streiner Ph.D. C.Psych.

Department of Psychiatry, University of Toronto, Toronto

Jennifer Gold LLB MPH

Ontario Medical Association, Toronto

Nathan Taback PhD

St. Michael’s Hospital, University of Toronto

David Moher PhD

Ottawa Methods Centre, Ottawa Hospital Research Institute; Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa. Ottawa

**Corresponding Author:** Paula A. RochonMD MPH

Address: Women’s College research institute

790 Bay Street Toronto

Telephone: 416-351-3732 x2711

Fax: 416-351-3746

e-mail: [paula.rochon@utoronto.ca](mailto:paula.rochon@utoronto.ca)

**Abbreviated Title**: **The Financial Conflicts of Interest Checklist for Investigators.**

**Acknowledgments:** We would like to thank Peter Anderson for technical assistance. We would also like to thank the external experts who were collaborators on this project and provided their valuable insight for our *fCOI Checklist* item development. The names of external experts are listed in Appendix 1.

**Funding/Support:** This project was funded by Canadian Institutes of Health Research (CIHR) Grant entitled Evaluation of the Integrity of Clinical Research in Canada EIC – 77338. Dr. Moher is supported by a University of Ottawa research Chair.

**Conflicts of Interest:** Joel Lexchin was retained by a law firm representing Apotex to provide expert testimony about the effects of promotion on the sales of medications. He has also been retained as an expert witness by the Canadian federal government in its defense of a law suit launched challenging the ban on direct-to-consumer advertising of prescription drugs in Canada. No conflicts reported for rest of the authors.

**Role of the Sponsors:** The funding organizations did not participatein the design or conduct of the study, in the collection, analysis,or interpretation of the data, or in the preparation, review,or approval of the manuscript. Dr. Rochon had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Abstract**

**Word count = 371**

**Background**: To develop a simple, comprehensive tool to help investigators identify and report their potential financial conflicts of interest (fCOI) in relation to a specific clinical research study.

**Methods**: Between January 2007 and April 2009, we developed the *fCOI Checklist* using a three phase process (pre-meeting item generation, consensus meeting, and post-meeting consolidation). In the pre-meeting item generation phase, the initial *Checklist* items were drafted by our research team based on published literature of initiatives that targeted specific aspects of fCOI. The *Checklist* was revised using a modified Delphi process. We obtained ratings on *Checklist* items from our invited external experts (n=19), team members (n=12), and research staff (n=4) for two sequential *Checklist* iterations. All reviewers used a five point adjectival rating scale (1 least to 5 most important) and provided free text suggestions to improve items. In the consensus meeting phase, the revised *Checklist* was discussed at a day long meeting in Toronto where twenty-eight individuals participated. In the post meeting consolidation phase, the *Checklist* was piloted for usability; an Example document, Explanation document, and a fill-able [Portable Document Format](http://www.adobe.com/products/acrobat/adobepdf.html) (PDF) version version were created. A day long meeting of team members was held to finalize the *Checklist*

**Results**: The modular *fCOI Checklist* contains four sections (i.e. administrative, study, personal financial, and authorship information) divided into six modules, containing 14 items and their related sub-items along with a glossary of terms. A fill-able PDF version contains skip functions with items linked directly to definitions and can be completed in less than 20 minutes. Different modules within the *fCOI Checklist* should be completed at different transition points over the course of the study and updated information can be appended to the originally completed *fCOI Checklist* for submission to stakeholder groups for their review.

**Conclusions:** We developed a simple comprehensive *fCOI Checklist* to help investigators identify and report information related to fCOI to stakeholder groups.  We consider this *Checklist* to be a living document.  We invite comments and suggestions for improvement.  We ask stakeholder groups to endorse the use of this document.  Increasing transparency through standardized reporting about fCOI in research will be an important step to reducing the influence of fCOI on research outcomes and ultimately improving public confidence in research.

.

A financial conflicts of interest (fCOI) in the research context is defined as a situation where “professional judgement concerning a primary interest (e.g. a patient’s welfare or the validity of research) tends to be unduly influenced by a secondary interest (e.g. financial gain)” (1) When investigators receive financial benefit related to their research , there is concern that this benefit may influence, or be perceived to influence, the investigators’ judgement and therefore their behaviour (2). Studies in which the investigators experienced fCOI have been linked to bias in research design (3), analysis (4-6) decision to publish (7), unsupported study conclusions (8) and serious adverse events for research participants (9, 10). In order to maintain public trust in research, it is important that potential fCOIs are disclosed so that this information can be reviewed and where indicated steps can be taken to manage its effects.

Our overall goal is to sensitize investigators to situations that may make their study susceptible to the effects of fCOI and to provide a report of the situation so that the appropriate groups (e.g. research ethics boards, conflicts of interest committees, funding agencies, journal editors) can in turn assist with developing management strategies to minimize the potential harm. There is little guidance available to investigators to help them report information relevant to potential conflicts of interest in their research. Information related to financial conflicts of interest needs to be reported to stakeholders for assessment and management as investigators do not necessarily see their own potential fCOI.(11, 12) While specific strategies have been developed to disclose aspects of fCOI, few strategies have approached the problem in a comprehensive manner. We designed *the fCOI Checklist* for clinical research studies. While clinical trials may be an important study design, all studies have the potential to be influenced by fCOIs.

We developed a simple, comprehensive *Checklist* that investigators can use to describe their study and provide a structured report of the potential fCOI situations they may have related to their role in a particular study.

**Method**

We developed the *fCOI Checklist* using a three phase process (pre-meeting item generation, consensus meeting, and post-meeting consolidation). Contributors to the development of this *Checklist* are listed in Appendix 1.

Pre-meeting Item Generation

The process used to develop the *fCOI Checklist* was adapted from a recent report on developing health research reporting guideline (13) and is outlined in Figure 1. The *fCOI Checklist* items were generated initially by our *research team* (expertise in research, ethics boards, law and policy, trial registration, research administration, clinical research, and research guideline development (Consolidated Standards of Reporting Trials (CONSORT) and Enhancing QUAlity and Transparency Of health Research (EQUATOR)-Network) and were based primarily on the published literature. We identified the *fCOI Checklist* items directly from international initiatives that targeted specific aspects of fCOI. For example, items related to the module on trial registration were consistent with the *World Health Organization* trial registration initiative (14) and items in the Study Team and Funder Relationship Profile module and the Authorship Information section were consistent with the *International Committee of Medical Journal Editors* (*ICMJE)* guidelines. (15, 16)

To refine this list, we used a modified Delphi process. Three groups of reviewers (i.e., research team (n=12), external experts (n=19) (expertise in trial registration, research guideline development (CONSORT, EQUATOR), ethics review, government administration policy, health law, medical journals, media) and our research support staff (n=4)) provided ratings. The research support staff was included to provide a perspective from non-experts with experience in the research process.

We created a five point adjectival rating scale (1 least to 5 most important) Reviewers were sent two sequential electronic versions of the *fCOI Checklist* (Version One and Version Two). They ranked each item and entered free text suggestions for improving the item. Not all reviewers were available for both rating sessions (29 participated in version one, 24 participated in version 2).

Consensus Meeting

Twenty-eight people participated in a day long consensus meeting that took place in October 2007 in Toronto, Ontario Canada. There were 11 team members and 4 research support staff that attended the meeting. Thirteen external experts participated using web-teleconference connection from four countries. *FCOI Checklist Version 3* was presented at theconsensus meeting for item discussion and to identify areas for revision. The meeting was organized into four thematic sessions reflecting major stakeholder groups (clinical trial registry users, journal editors, funders/policy makers, and legal/ethics). Each external expert participated in one of these sessions based on their expertise. Each session began with an overview of the *Checklist* project. The chair for the session provided a description of the specific thematic area to be discussed and led the discussion for that session. The discussion focused on items where there was disagreement about their value based on the pre-meeting item ratings.

Post Meeting Consolidation

The post meeting consolidation phase involved three steps. First, the research team incorporated the suggested changes made at the consensus meeting into the *fCOI Checklist Version 4.*  We piloted this version of the *Checklist* for initial usability using a small group of investigators. We created an Example document with examples of good reporting, a *Checklist* Explanation document, and a fill-able PDF version of *Checklist*.

Second, the research team met in Toronto for a one day consolidation meeting. At this meeting the research team reviewed the *Checklist* by module and item. Where required, rewording and reorganization of items was done to promote clarity. A decision was made to include a glossary of terms. Suggestions were made for refining the PDF option of the *Checklist*. In addition, we further discussed the process envisioned to implement the *fCOI Checklist* in practice.

The suggestions made for the *Checklist* were incorporated into the *fCOI Checklist* Version 5. The fill-able PDF version of the *Checklist* was revised and items were linked directly to definitions to facilitate understanding and common usage of the items. The corresponding Example *Checklist* and the Explanation document were revised. This *Checklist* was again evaluated in a final usability survey and after minor revisions, the final *fCOI Checklist* was created along with the corresponding fill-able PDF version.

Ethical review and approval was obtained from the Baycrest Centre Research Ethics Board and Women’s College Research Institute Ethics Board, where the principal investigator was located. Financial support was provided by the Canadian Institute of Health Research operating grant number EIC-77338.

**Results**

Table 1 contains the *fCOI Checklist*. This *Checklist* is to be completed by an individual in the context of a specific study. Included in the *fCOI Checklist* is a glossary of terms using definitions mainly obtained from the WHO (17) (18) and ICMJE (16). The *fCOI Checklist* is also available as a fill-able PDF option (see supplement 1). An advantage of the PDF format is that it provides a skip function that allows investigators to complete only sections that are relevant to them at the time of *Checklist* completion. The PDF version also contains a glossary that is easily available by clicking on individual items to further promote clarity.

The *Checklist* contains four sections (i.e., administrative information, study information, personal financial information, and authorship information). These sections are divided into a total of six modules that contain 14 items and their related sub-items. The Administrative Information section contains study and investigator administrative information and a record of the date(s) when the *fCOI Checklist* was initiated or updated. The Study Information section contains three modules (i.e., funder profile, contract profile, study team and funder relationship profile) and the Personal Financial Information section contains one module (financial profile). The Authorship section contains one module (authorship profile). Table 2 shows the *fCOI Checklist* along with examples of good reporting where free text responses are required. Table 3 provides explanations for each of the six modules of the *fCOI Checklist*.

The *fCOI Checklist* was designed as a ‘living’ document. Different modules within the *fCOI Checklist* should be completed at different transition points over the course of the study. In general, the *fCOI Checklist* would be completed in two stages: prior to study inception (Modules A to E) and after study completion (Modules F). For example, investigators would complete the Administrative Information section of the *fCOI Checklist* when they initiated the study. The Authorship Information section should be completed when manuscripts were in preparation for publication. Some sections of the *fCOI Checklist* (e.g., personal financial information section) would require updating if the investigator’s financial profile changed. We anticipate that updated information would be appended to the originally completed *fCOI Checklist*. This is done to maintain a permanent record of information related to fCOI throughout the course of the study.

We recognize that clinical research and in particular clinical trials are generally conducted by a team of investigators.  We anticipate that each investigator should independently complete the *fCOI Checklist*.  When multiple investigators are involved in the research we expect that information from the *Checklist* will need to be collated.  The overall study official (in the case of clinical trials) or the study guarantor (in the case of a manuscript submission) will likely be the most knowledgeable person to provide administrative information about the study and should be responsible for collating these sections of the *Checklist* (i.e., Module A- Administrative Profile, Module B- Funder Profile, and Module C- Contract Profile).

We conducted two small usability studies to assess the *fCOI Checklist* for investigators conducting clinical studies. Of the seventeen investigators surveyed, most (76%) had served as an investigator in a randomized trial. Most (65%) respondents reported no difficulty in answering the questions and 94% required less than 20 minutes to complete the entire *Checklist*.

**Discussion**

We created a simple *fCOI Checklist* that is non-judgmental. Our *fCOI* *Checklist* provides a structured report that can be directly reviewed by stakeholders who review an investigator’s fCOI information as part of the research process. This completed *fCOI Checklist* could be used by Research Ethics Boards (REBs)/ Institutional Review Boards (IRBs), who require information on fCOI to asses the potential ethical implications of fCOI and to identify situations where an investigator may have fCOI that may require management. Funding agencies may request this information to disclose information about fCOI as part of their review process. Academic institutions may use this information to assess potential fCOI situations and to help with management strategies. Journal editors can use the *fCOI Checklist* to help identify studies where an investigator’s fCOI has the potential to contribute to biased reporting of information published in scientific journals. Further, this *Checklist* can facilitate sharing of information related to conflicts of interest among the involved stakeholders. When an initial report suggests possible conflicts of interest, the situation can be referred to a conflicts of interest committee for further review. The Institute of Medicine report outlines a model of steps that can be used to identify and respond to such a conflict (10)

An important feature of our *fCOI Checklist* is that it is a prospective record completed by investigators as the clinical research moves through its various stages. This offers advantages over the current approach used by separate, disjointed disclosures to funding agencies, ethics review boards, research administration and

journal editors. Using a *fCOI Checklist* initiated at the start of the study and updated (at study transitions points and when information changed) and appending the completed *fCOI Checklist* to the manuscript submission package provides a more comprehensive picture about an investigator’s potential fCOI. Second, by completing the *fCOI Checklist* in a prospective manner, potential fCOI situations may be identified at an earlier stage so that appropriate management strategies can be put in place to help minimize potential harms. This opportunity to intervene is lost when fCOI information is collected only upon study completion. Also investigators may have unintentionally allowed fCOI situation to affect their judgement during the conduct of a study, but divest themselves of the situation before publication; the fCOI would not be apparent to the journal editors using the current reporting mechanism. Finally, the type of fCOI information required by journals varies substantially. Our *fCOI Checklist* would help standardize the information submitted to journals.

Our *Checklist* may have an educational role. The *Checklist* is designed to be completed individually by each investigator. We recognize that clinical research is generally conducted by a team of investigators and that not all investigators will have access to the same information as the overall study official. By providing all investigators with the same set of questions, irrespective of their role in the study, our goal is to sensitize investigators to information that they should know about their clinical research study. This is a first step in an educational process. Academic policies do not always provide investigators with clear guidance to assist them in identifying and reporting situations that may be related to fCOI. Further, national surveys of fCOI policies in academic settings suggest that these policies are often incomplete,(19-21) fragmented (19) and difficult for investigators to understand (19, 22) all of which limit their practical usability by investigators. While the *Checklist* will likely initially be completed by investigators on the study, we have created the *Checklist* so that it can be completed by other team members. As awareness of the fCOI issues grows, the *Checklist* could be completed by other study team members, such as study co-ordinators, research assistants and study nurses whose judgement can also be affected by fCOI, so that all team members may become more aware of conflicts of interest situations.

This *fCOI Checklist* has been designed as an attachment to the Consolidated Standards of Reporting Trials (CONSORT) statement (23) as it can be appended to the existing CONSORT statement and its extensions. We recognize that this *fCOI Checklist* can have much broader application than our original intent. We anticipate that this *Checklist* will be adapted for use for other types of studies such as basic science studies. The *Checklist* can also be adapted for use outside of the research setting. A modified version of this *Checklist* could be completed by grant review panel members who are making funding decisions; guideline panel members who are making decisions about best therapies; board members who are making decisions about the direction of an academic organization; and by expert witnesses who are providing expert opinions in court proceedings or tribunals. Accordingly, we designed the *fCOI Checklist* with sections, modules, and items so that it can be tailored for use in a range of different purposes including those that we may not yet have anticipated.

This *Checklist* has potential limitations. First, our *Checklist* focuses on financial conflicts of interest. We recognize that there are nonfinancial conflicts of interest. Financial conflicts of interest are the most quantifiable. Second, we recognize that while there are only fourteen items, there are more in-depth sub items that may take longer to complete. Our user surveys suggest that the *Checklist* can be completed in under 20 minutes. Importantly, the entire *Checklist* need not – and likely should not – be completed at one time. As we have recommended, different modules should be completed as different stages of the research. Further, the web version of the *Checklist* includes the ability to skip sections that are not relevant at a given time, facilitating completion. Finally, while the *fCOI Checklist* is based on a simple concept, using the *fCOI Checklist* in practice is more complex and will likely require the development of local processes depending on specific stakeholder needs.

**Conclusion**

We developed a simple comprehensive *fCOI Checklist* to help investigators identify and report information related to FCOI to stakeholder groups.  We consider this *Checklist* to be a living document.  We invite comments and suggestions for improvement of this *Checklist* and suggestions for adaptations.  We ask Stakeholder groups such as REBs, funding agencies, academic institutions, those responsible for clinical trial registries, and journal editors to endorse the use of this document.  Increasing transparency through standardized reporting about fCOI in research will be an important step to reducing the influence of fCOI on research outcomes and ultimately improving public confidence in research.

**References:**

**Financial Conflicts of Interest Checklist for Clinical Research Studies**

1. Thompson DF. Understanding financial conflicts of interest. N Engl J Med1993 Aug 19;329(8):573-6.

2. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA2000 Jan 19;283(3):373-80.

3. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ [Review]. 2003 May 31;326(7400):1167-70.

4. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994 Jan 24;154(2):157-63.

5. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA2003 Aug 20;290(7):921-8.

6. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA2006 May 17;295(19):2270-4.

7. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ2003 May 31;326(7400):1171-3.

8. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med1998 Jan 8;338(2):101-6.

9. Marshall E. Gene therapy death prompts review of adenovirus vector.[see comment]. Science1999 Dec 17;286(5448):2244-5.

10. Lo B, Field MJ. Conflict of Interest in Medical Research, Education, and Practice

Institute of Medicine2009. Report No.: ISBN-13: 978-0-309-13188-9

11. Warner TD, Gluck JP. What do we really know about conflicts of interest in biomedical research? Psychopharmacology (Berl)2003 Dec;171(1):36-46.

12. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry.[see comment]. JAMA2003 Jul 9;290(2):252-5.

13. Moher D, Schulz KF, Simera I, Altman DG. Developing guidelines for reporting health research: points to consider.

14. ICTRP. International Clinical Trials Registry Platform (ICTRP). WHO; [cited 2008 February 20]; Available from: http://www.who.int/ictrp/network/list\_registers/en/index.html.

15. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. 2004 October [updated October 2008].

16. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. 2008 [cited 2009 January 30]; Available from: http://www.icmje.org/.

17. ICTRP. Glossary:International Clinical Trials Registry Platform (ICTRP): World health organization.Available from: **http://www.who.int/ictrp/glossary/en/**

18. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products: WHO technical report series 1995.

19. Rochon PA, Sekeres M, Lexchin J, Moher D, Wu W, Kalkar SR, et al. Institutional Financial Conflicts of Interest at Canadian Academic Health Science Centres: A National Survey.

20. Ehringhaus SH, Weissman JS, Sears JL, Goold SD, Feibelmann S, Campbell EG. Responses of medical schools to institutional conflicts of interest. JAMA. [Research Support, Non-U.S. Gov't]. 2008 Feb 13;299(6):665-71.

21. Ehringhaus S, Korn D. U.S. Medical School Policies on Individual Financial Conflicts of Interest - Results of an AAMC Survey. Washington DC: AAMC2004 September.

22. Williams-Jones B, MacDonald C. Conflict of Interest Policies at Canadian Universities: Clarity and Content. Journal of Academic Ethics2007 October.

23. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA2001 Apr 18;285(15):1987-91.

24. Authorship Guidelines: Faculty Policies on Integrity in Science, Faculty of Medicine Harvard Medical School

Available from: http://www.hms.harvard.edu/integrity/authorship.html.

25. Glossary of Terms: Human Resources and Skills Development Canada

2008; Available from: http://www.hrsdc.gc.ca/eng/workplaceskills/oles/callforproposals/glossary.shtml.

26. 42 CFR 50 (f), (2000).

27. Research Governance, Scientific and Ethics Review: Glossary : The University of Sheffield Available from: http://www.shef.ac.uk/snm/research/research\_governance/glossary.html.

28. Ghost Writing Initiated by Commercial Companies

Available from: http://www.wame.org/resources/policies#ghost.

29. ClinicalTrials.gov. Protocol Data Element Definitions

ClinicalTrials.gov; 2008; Available from: http://prsinfo.clinicaltrials.gov/definitions.html.

30. Asghar R, Banajeh S, Egas J, Hibberd P, Iqbal I, Katep-Bwalya M, et al. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study).[see comment]. BMJ 2008 Jan 12;336(7635):80-4.

31. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008 Dec 11;359 (24):2521-32.

32. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine2007 May 10;356(19):1915-27.

33. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature2005 Apr 14;434(7035):917-21.

34. Petryna A. Ethical variability: drug development and globalizing clinical trials. American Ethnologist 2005;32:183-97.

35. Vickers A, Goyal N, Harland R, Rebecca R. Do Certain countries produce only positive results? A systematic review of controlled trials. Controlled Clin Trials 1998;19:159–66.

36. Chalmers I. Underreporting research is scientific misconduct. JAMA1990 Mar 9;263(10):1405-8.

37. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE2008;3(8):e3081.

38. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004 May 26;291(20):2457-65.

39. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration--looking back and moving ahead. New England Journal of Medicine2007 Jun 28;356(26):2734-6.

40. U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of 2007 or FDAAA), Title VIII, Section 801 2007.

41. Blumenthal D, Campbell EG, Causino N, Louis KS. Participation of life-science faculty in research relationships with industry. N Engl J Med1996 Dec 5;335(23):1734-9.

42. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med1996 Mar 1;124(5):485-9.

43. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. [Review.]. 2003 Jan 22-29; 289(4):454-65.

44. Naylor C. Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. . CMAJ 2002;166:453-6.

45. Mello MM, Clarridge BR, Studdert DM. Academic Medical Centers’ Standards for Clinical-Trial Agreements with Industry. N Engl J Med [special article]. 2005; 352: 2202-10.

46. Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med2005 May 26;352(21):2160-2.

47. Bodenheimer T. Uneasy alliance--clinical investigators and the pharmaceutical industry. N Engl J Med2000 May 18;342(20):1539-44.

48. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science. Evidence from a national survey of faculty. JAMA1997 Apr 16;277(15):1224-8.

49. Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases. [updated November 2008; cited 2009 February 18]; Available from: http://www.ifpma.org/documents/NR10990/Revised\_Joint\_Industry\_Position\_26Nov08.pdf.

50. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industry-initiated clinical trials. JAMA2006 Apr 12;295(14):1645-6.

51. Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, Hojgaard L, et al. Sponsorship, authorship, and accountability. N Engl J Med2001 Sep 13;345(11):825-6; discussion 6-7.

52. Authorship. WAME; 2005 [cited 2009 January 31]; Available from: http://www.wame.org/resources/policies#trialreg.

53. CONSORT. 2009.

54. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA2008 Apr 16;299(15):1800-12.

55. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials.[see comment]. PLoS Medicine / Public Library of Science2007 Jan;4(1):e19.

56. Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. PLoS clinical trials2006 May;1(1):e1.

57. Harris G. F.D.A. Limits Role of Advisers Tied to Industry.New York Times. 2007.

58. Djulbegovic B, Angelotta C, Knox KE, Bennett CL. The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol2007 Aug 20;25(24):3567-9.

59. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota.[see comment]. JAMA2007 Mar 21;297(11):1216-23.

60. Rowley BD, Van Harrison R, Thomas AM. What You Should Know About Gifts to Physicians from Industry

Module 3: Professionalism & Gifts to Physicians from Industry. American Medical Association; 2003;

Available from: http://www.ama-assn.org/ama1/pub/upload/mm/437/ama\_m3\_ph.pdf

61. Campbell EG, Louis KS, Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA1998 Apr 1;279(13):995-9.

62. Commercialization - Your Health Research Dollars at Work 2006-2007.Canadian Institutes for health Research

CIHR; [cited 2008 October 6th]; Available from: http://www.cihr-irsc.gc.ca/e/35194.html.

63. The Health Technology Exchange – HTX.ca. [cited 2008 October 6th]; Available from: http://www.mri.gov.on.ca/english/programs/htx-program.asp.

64. Bayh-Dole Act Pub L.No.96 -517,35 USC 1980.

65. Kimmelman J. Inventors as investigators: the ethics of patents in clinical trials. Acad Med2007 2007 Jan;82((1)):24-31.

66. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA1998 Jul 15;280(3):222-4.

67. Guidelines on good publication practice: Committee on Publication Ethics (COPE)